Clinical trial
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
NCT00355407 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00355407 |
|---|---|
| Title | Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation |
| Official title | A Pilot Study of Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Amgen Industry Brigham and Women's Hospital |
| Status | Completed |
| Study type | Interventional |
| Conditions | Hematologic Malignancies |
| Intervention type | Drug |
| Interventions | Darbepoetin alfa |
| Enrollment | 31 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jul 21, 2006 |
| Last update posted | Mar 13, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: